Advertisement


Elias Jabbour, MD, on CML and ALL: Olverembatinib Overcomes Ponatinib Resistance

2022 ASH Annual Meeting and Exposition

Advertisement

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses an analysis confirming that olverembatinib is a potentially viable treatment option for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL), including those with CML whose disease did not respond to ponatinib or asciminib, or who had a T315I mutation (Abstract 82).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Major progress for accomplishing in CML management. Today somebody with CML can expect to have a normal lifespan. However, with patient relapse, this can be a problem and we have multiple TKIs and multiple end of therapy. We know that patient who fail multiple TKIs can have an additional outcome and this was an error of unmet need, and that's why we and others exploring a drug called Olverembatinib in CML patients who failed multiple agents. The drug was first tested in Chinese population and the drug was found to be effective. In fact, it does inhibit the BCR able kinese protein mutated or wild type and [inaudible 00:00:42] and significant activity in China with an update shown at ASH 2022 with five years update. The dose approved in China was 40 milligram every other day. The next question was, can we move this drug to the USA? And as an elite PI, I took the drug to USA and we designed a study called bridging Study phase one B study to assess first the pharmacokinetics to see if the drug is metabolized same way as in Chinese population. And in this trial we have three arms exploring different dose, 40 milligram, 30 milligram, 50 milligram every other day, 3, 3, 2 ratio. And we enroll patient in a chronic phase advance stage disease. The primary point was to assess the PKS of the study, PK of the drug, and subsequently of course, efficacy and safety. Where all 51 patients and this patient have failed multiple TKIs, at least two. But the measure that treat TKIs failure, they have risk factor for cardiovascular events, hypertension, and dyslipidemia around a third of them at hypertension. And then 350 eye mutation was seen in a third of this patient, which we know that is a bad signal because none of the TKIs available except few do work on these mutations. What we reported that the drug is quite effective in patient who failed multiple agents, still around 80% were able to regain their C C Y R and 50% were able to achieve a deep molecular response, what they call MMR. Furthermore, in a group of patients who failed Ponatinib, one of the most important drug, 70% were able to respond again, which is the first ever seen. Of course the numbers are small still, but it gives a good signal that drug is effective in patient who failed Ponatinib. They achieve a C C Y R and MMR. We've seen activity as well inpatient who had 350 eye mutation and without this mutation. Furthermore, the follow up of the study was around eight to nine months. We've seen that this response are durable. In fact, out of the eight patients who achieved the deep molecular response or MMR, seven of the eight are maintaining the response. One of them was taken off the transplantation. In advance stage disease, we've seen similar activities. Two of the six patients enrolled a valuable, responded nicely despite failing prior therapies. This patient failed Ponatinib, and Asciminib, so the efficacy is there. When it comes to safety, nothing measured. In fact, we've seen that the myelosuppression is lower than was seen in the Chinese population. The side effect, the main one was hyper pigmentation of the skin, but of nonclinical significance. Now we've seen increase of CPK, not clinically relevant. We look extensively at the vascular event because it was reported with the other TKIs. We have two patients and a [inaudible 00:03:34] one and joint [inaudible 00:03:34] and cardiac failure were possibly related, but they maintained the treatment. So the treatment was effective and maintained. Those who stopped therapy, stopped therapy mainly for to go to transplantation. So now finally we can say from the trial that the drug is safe and effective in patient population who fail everything and their unmet need for them. Moving forward what's next is still trying to define what is the best dose schedule. We believe 40 milligram every other day, but still we have to compare 30 and 40 because they're identical and moving forward for the path for approval, I think maybe the drug should be tested in patient with multiple failure and move later on to randomized trial in a second line or frontline that we to be seen based on how the data mature and evolve.

Related Videos

Lymphoma

Eva Hoster, PhD, on Mantle Cell Lymphoma: Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance

Eva Hoster, PhD, of Munich University, discusses results from the European MCL Elderly Trial, which confirmed the strong efficacy of rituximab maintenance in minimal residual disease (MRD)-negative patients with mantle cell lymphoma (MCL) after induction. Omitting maintenance based on MRD-negativity is thus discouraged. Considering the short time to progression, more effective treatment strategies should be explored in MRD-positive patients to improve long-term prognosis (Abstract 544).

Leukemia
Genomics/Genetics

Irene Roberts, MD, on Leukemogenesis in Infants With Trisomy 21

Irene Roberts, MD, of Oxford’s Weatherall Institute of Molecular Medicine, discusses children with Down syndrome, who have a more than 100-fold increased risk of developing acute myeloid leukemia before their fourth birthday compared to children without Down syndrome. Their risk of acute lymphoblastic leukemia is also increased by around 30-fold. Dr. Roberts details current knowledge about the biologic and molecular basis of this relationship between leukemia and Down syndrome, the role of trisomy 21 in leukemogenesis, and the clinical implications of these findings.

Leukemia
Issues in Oncology

Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends

Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute myeloid leukemia (AML). Between 2000 and 2019, AML mortality was the highest in Whites and the lowest in American Indians or Alaska Natives. The highest rate of increase in mortality was seen in Asians or Pacific Islanders. Dr. Al Armashi talks about the many variables that might contribute to these inequalities (Abstract 600).

Multiple Myeloma

Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).

Lymphoma

Paolo F. Caimi, MD, on DLBCL: Outcomes After R-ICE Chemoimmunotherapy

Paolo F. Caimi, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses new findings showing that patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response after salvage therapy with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) can achieve long-term disease control, regardless of the time to relapse from initial therapy, particularly if they proceed to autologous stem cell transplant (ASCT). These results suggest that second-line chemotherapy followed by ASCT and/or CAR T-cell therapy for chemosensitive and chemorefractory patients may maximize patient outcomes, regardless of time to relapse (Abstract 156).

Advertisement

Advertisement




Advertisement